Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial

Next Previous
X
Search
Trial Profile

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary) ; Heparin
  • Indications COVID 2019 infections; Myocardial infarction; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms STARS

    • Most Recent Events

    • 18 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 27 Sep 2021 Primary endpoint has not been met (PaO2/FiO2 improvement from pre-to-post intervention) , according to Results published in the Chest
    • 27 Sep 2021 Results published in the Chest

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top